secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001104659-24-087031
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Therapeutics Q2 2024 net loss $31.5M; cash $511.8M; EDG-7500 Phase 1 complete
--------------------------------------------------------------------------------

- Net loss of $31.5M ($0.34 per share) vs $28.5M in prior quarter; no product revenue.
- Cash and marketable securities $511.8M as of June 30, 2024.
- Completed Phase 1 SAD/MAD trial of EDG-7500 in healthy volunteers; Phase 2 CIRRUS-HCM enrolling.
- Sevasemten: CANYON Phase 2 data in Becker expected Q4 2024; GRAND CANYON pivotal cohort ongoing.
- LYNX Phase 2 in Duchenne data expected Q4 2024; Phase 3 planned H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465924087031/0001104659-24-087031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465924087031/tm2420690d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-087031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer